Abacavir/Dolutegravir/Lamivudine (Triumeq)

The Latest

This Week in HIV Research: The Racism of Perceived Risk

June 6, 2019: HIV/STI risk perceptions differ by race; psychosocial issues and HIV risk among young trans women; switching to dolutegravir/atazanavir; reports of severe hepatotoxicity on dolutegravir.

By Barbara Jungwirth and Myles Helfand

Large French Study Examines Neuropsychiatric Side Effects With Integrase Inhibitors

This will likely become the landmark study about the overall rate of neuropsychiatric side effects with this class of medicines over the next several years.

By Sean R. Hosein for Canadian AIDS Treatment Information Exchange

Dolutegravir More Effective Than Efavirenz at Achieving Viral Suppression During Late-Term Pregnancy, New Study Shows

Unlike some previous studies that focused on early pregnancy, this study showed no associated congenital disabilities with either drug.

By Sony Salzman

De-Simplifying Single-Tablet Regimens for HIV Treatment

A Canadian study of this cost-saving approach found high acceptance of de-simplification among people already on a single-tablet regimen, and even higher rates among people who were just initiating single-tablet treatment.

By Sean R. Hosein for Canadian AIDS Treatment Information Exchange

An Overview of Triumeq (Abacavir/Dolutegravir/Lamivudine)

Brand Name: Triumeq Other Name(s): ABC/DTG/3TC, abacavir sulfate/dolutegravir sodium/lamivudine Drug Class: Combination Drugs

By AIDSinfo

Triumeq Virologically Superior to Boosted-Atazanavir Regimen in Women's Trial

A fixed-dose combination of dolutegravir plus abacavir/lamivudine proved virologically superior to once-daily ritonavir-boosted atazanavir plus tenofovir/emtricitabine, in a large study of women with HIV.

By Mark Mascolini

Switching to Single-Pill Regimen Controls HIV as Well as Other Standard Treatment

New data show equal control of HIV levels when switching from a standard multi-pill regimen to the single-tablet regimen of Triumeq.

By Project Inform

Switching to Abacavir/Dolutegravir/Lamivudine (Triumeq) Maintains Undetectable Viral Load

Paul Sax, M.D., recaps an important study presented at ICAAC 2015, which highlighted 24-week results for patients switching to abacavir/dolutegravir/lamivudine (Triumeq).

By Paul E. Sax, M.D. for NEJM Journal Watch